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CASE PRESENTATION
An 18 year old female with no past medical history awoke with a severe
generalized headache associated with nausea, vomiting and photophobia.
Two weeks prior, she had nasal congestion, mild sore throat, and
productive cough with yellow sputum which resolved but fatigue persisted.
She was taking oral contraceptives. Physical exam was normal except for
significant fatigue. Pertinent labs included a normal WBC, H/H, PT/INR
and aPTT. Platelets were 20,000 platelets/mm3. CT Head demonstrated
right transverse sinus thrombosis, with empty delta sign. MRI revealed
extensive right transverse sinus thrombosis with extension into the right
internal jugular vein. Peripheral smear showed marked thrombocytopenia
with occasional large and giant forms, some neutrophils with toxic
granulation, and occasional reactive-appearing lymphocytes. Her LFTs
were mildly elevated with AST 116, ALT 120 Unit/L. Abdominal ultrasound
revealed hepatomegaly with mild echogenicity and a normal sized spleen.
Viral hepatitis screen was negative. Absolute CD4 count was low
(182/mm3); HIV negative. Hypercoagulable workup negative. ANA
negative. Anti-heterophile antibody negative. Epstein-Barr antibody to
early antigen positive. Epstein-Barr viral capsid antigen IgG positive but
IgM negative. Epstein-Barr antibody to nuclear antigen positive. She was
diagnosed with Epstein-Barr virus infectious mononucleosis causing
immune thrombocytopenia, for which she was treated with
dexamethasone and intravenous immunoglobulin (IVIG). The infection
plus oral contraceptives likely resulted in the cerebral venous sinus
thrombosis, for which she was treated with a heparin drip and then
transitioned to warfarin. Oral contraceptives were discontinued. She
received Keppra for seizure prophylaxis. On day 2, her platelets dropped
to 9,000 platelets/mm3, but then rose to normal by day 12. Her low CD4
count, mildly elevated LFTs, hepatomegaly and severe fatigue were
attributed to the Epstein-Barr virus.
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EPSTEIN-BARR VIRUS (EBV) AND
IMMUNE THROMBOCYTOPENIA (ITP)
Background. Epstein-Barr virus infection has been associated with a
variety of hematologic abnormalities, including immune thrombocytopenia,
hemolytic anemia, aplastic anemia, thrombotic thrombocytopenic
purpura/hemolytic-uremic syndrome, and disseminated intravascular
coagulation. EBV appears to be a fairly common cause of ITP in children.
A study in China found EBV infection in 35/108 (32.4%) children
diagnosed with ITP1. Another study in China studied spleens of patients
with ITP and controls and found EBV expression in nine (21.4%) with ITP
compared to none in the control group2. Mild thrombocytopenia (100150,000 platelets/mm3) occurs in 25-50% cases of acute EBV infections,
but severe thrombocytopenia (<20,000 platelets/mm3) is rare; most cases
occur in children and young adults3,4.
Etiology. The etiology of thrombocytopenia in EBV is thought to be
immune-mediated5. In a review of EBV cases with thrombocytopenia, 7/16
patients (43%) had anti-platelet antibodies5. Historically splenomegaly was
considered etiologic; however, only half of EBV patients with severe
thrombocytopenia have splenomegaly, with no correlation between
thrombocytopenia and splenic size3.
Diagnosis. Heterophile antibodies may be absent at the time of
hematologic complications of EBV, so serologic studies should be done to
get the diagnosis3.
Treatement and Prognosis. In cases of ITP due to EBV, the
thrombocytopenia usually resolves spontaneously in days to weeks.
Treatment may not be needed, but often standard treatment for ITP
including steroids and immunoglobulins is given. Chronic
thrombocytopenia is very rare. Fatal cases are rare but may occur due to
cerebral hemorrhage or splenic rupture3.

TEACHING POINTS
1. Epstein-Barr virus can cause immune thrombocytopenia, particularly in
children and young adults.
2. The usual screening test for Epstein-Barr virus infectious
mononucleosis, the anti-heterophile antibody, can be negative at the
time of presentation with hematologic complications, so serology is
necessary for the diagnosis.
3. Cerebral venous sinus thrombosis main risk factors are prothrombotic
state (including oral contraceptives) and infection. Many cases have
multiple risk factors present.

CONCLUSIONS
This case illustrates a rare presentation of Epstein-Barr virus infection
causing both immune thrombocytopenia and cerebral venous sinus
thrombosis at the same time. The oral contraceptive pills likely played a
contributing role in addition to the Epstein-Barr virus infection in causing
the cerebral venous sinus thrombosis.

CEREBRAL VENOUS SINUS
THROMBOSIS (CVST)
Background. CVST is rare, with the incidence in children at 7 cases per
million and in adults at 3-4 cases per million, and it is more common in
women.
Etiology. The main risk factors are genetic or acquired prothrombotic state
and infection. Dual or multi-factorial causes have been identified in 44% of
cases. Oral contraceptives are a well-identified risk factor, as well as
pregnancy and post-partum.
Clinical Presentation. Headache is the most common presenting
symptom (89%); it is usually acute and severe, non-localized, and
worsened with Valsalva. Presentation can be variable. Some patients get
focal neurologic signs, like hemiparesis or acute aphasia (left transverse
sinus). Seizures occur in 40% of patients. Some patients present with
encephalopathy. Cavernous sinus syndrome is the least common
presentation, with oculomotor nerve palsies, facial pain, sensory loss in the
trigeminal nerve distribution, proptosis, and chemosis.
Treatment. Anticoagulation is recommended, with a goal INR 2-3. The
recommended duration varies, from 3 months for a known acute cause, to
6-12 months for idiopathic cases, to lifelong if the patient has multiple
prothrombotic factors or antiphospholipid antibody syndrome. Other
recommendations include aggressive management of intracranial
hypertension and medication for seizure prophylaxis. There are no
guidelines for endovascular treatment, which should be reserved for
severe cases.
Prognosis. Mortality for CVST is 8-14%, with death usually due to
intracerebral hemorrhage. Most cases (87%) result in complete recovery,
with the venous recanalization rate at 3 and 12 months at 85%. The
recurrence rate is 2.8%6.
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